anonymised participant-level data (Astellas)
90
Structured Review
Astellas
anonymised participant-level data
Anonymised Participant Level Data, supplied by Astellas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anonymised+data/anonymized+participant+level+data/pm39581908-203-6-13
Average 90 stars, based on 1 article reviews
Anonymised Participant Level Data, supplied by Astellas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anonymised+data/anonymized+participant+level+data/pm39581908-203-6-13
Average 90 stars, based on 1 article reviews
anonymised participant-level data - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia. Article Snippet: Non-author contributions and disclosures: No; Article Title: Maintenance therapy with the FMS ‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS ‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study Article Snippet: Researchers may request access to anonymized Article Title: Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Dialysis-Dependent Patients with Anaemia of Chronic Kidney Disease: A Retrospective Observational Study. Article Snippet: Researchers may request access to anonymised Article Title: Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study. Article Snippet: Researchers may request access to anonymized Article Title: Efficacy and Safety of Roxadustat in Patients with CKD: Pooled Analysis by Baseline Inflammation Status. Article Snippet: Data Availability Statement: Researchers may request access to anonymized Article Title: Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Article Snippet: Non-author contributions and disclosures: No; Agreement to Share Publication-Related Data and Data Sharing Statement: Researchers may request access to anonymized Article Title: Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC. Article Snippet: Aims: To compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus darolutamide + ADT for treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) using a matching-adjusted indirect comparison (MAIC).. Patients and methods: Individual patient data from ARCHES (NCT02677896; enzalutamide + ADT, N = 1150) were weighted and adjusted to match published aggregated data on baseline characteristics from ARANOTE (NCT04736199; darolutamide + ADT, N = 669).. The MAIC was anchored on the common comparator, placebo + ADT, and provided a (matching-adjusted) hazard ratio (HR) of enzalutamide versus darolutamide. Article Title: A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab. Article Snippet: Data Availability Statement Researchers may request access to anonymized |